According to a recent LinkedIn post from Prenuvo, the company is highlighting a new Focused Scan offering positioned as a faster, more accessible screening option compared with its existing whole-body scan. The post indicates the scan is non-invasive, radiation-free, takes under 30 minutes, and targets abnormalities in key areas rather than providing comprehensive whole-body imaging.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The post suggests Prenuvo is broadening its product mix to capture consumers who are interested in preventive health but hesitant about a full-body scan, potentially lowering the entry barrier to its services. For investors, this tiered approach could expand the addressable market, improve patient funnel conversion into higher-value services, and enhance recurring revenue potential if the Focused Scan becomes a standard first step in long-term preventive screening.
By emphasizing clinical rigor and positioning the Focused Scan as complementary rather than a replacement, the LinkedIn content points to a segmentation strategy rather than discounting the flagship product. This could help protect pricing power on whole-body scans while still enabling volume growth through a lower-commitment offering, which may support revenue diversification and strengthen Prenuvo’s competitive position in the preventive imaging segment.